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Abstract 
The aim of the study was to investigate the ability of a combination of bone marrow 
mesenchymal stem cells (BM-MSCs) with and without demineralized freeze-dried bone 
allografts (DFDBAs) to induce bone regeneration in calvarial defects in ovariectomized rats. 
Critical size defects were filled with a combination of demineralized freeze-dried bone 
allografts and bone marrow mesenchymal stem cells (BM-MSCs) or BM-MSCs alone. Eight 
weeks after calvarial surgery, the rats were sacrificed. The samples were analyzed 
histologically and immunohistochemically. No difference was observed in vascularization 
between groups C1 (animals with cranial defect only, control group) and O1 (animals with 
cranial defect only, ovariectomy group). Intramembranous ossification was observed at a 
limited level in groups C2 (animals with cranial defect with MSCs, control group) and O2 
(animals with cranial defect with MSCs, ovariectomy group) compared to C1 and O1. In 
group C3 (animals with demineralized freeze-dried bone allografts with MSCs, control 
group), the fibrous structures of the matrix became compact as a result of a bone graft having 
been placed in the cavity, but in group O3 (animals with demineralized freeze-dried bone 
allografts with MSCs, ovariectomy group), the fibrous tissue was poorly distributed between 
the bone grafts for the most parts. We conclude that the insertion of BM-MSCs enhances bone 
healing; however, the DFDBA/BM-MSC combination has little effect on overcoming 
impaired bone formation in ovariectomized rats. 
Key words: bone healing, bone marrow mesenchymal stem cells (BM-MSCs), 
demineralized freeze-dried bone allografts (DFDBAs), ovariectomy, calvarial defect 
 
 
INTRODUCTION 
 Estrogen deficiency is an important cause of postmenopausal bone loss. It leads to an 
imbalance in osteoblast and osteoclast number. The effect of estrogen on bone metabolism is 
mediated by proinflammatory cytokines. In estrogen deficiency conditions, monocytes and 
macrophages produce large amounts of the cytokines IL-1, IL-6, TNF-α, granulocyte-
macrophage colony-stimulating factor, macrophage colony-stimulating factor, and 
prostaglandin-E2 that stimulate mature osteoclasts, and consequently induce bone resorption 
(1). 
 Several studies have suggested that there is a relationship between systemic low bone 
density and the onset of periodontitis, which is characterized by the loss of connective tissue 
and alveolar bone, and risk factors, such as genetics, environmental factors, hormone levels, 
smoking and diabetes, associated with osteoporosis. Authors have also remarked that 
osteoporosis may have an effect on the progression of periodontitis via the loss of bone 
mineral density in the maxilla and mandible in postmenopausal women (2,3). 
Diminished bone density enhances the destruction of alveolar bone, which complicates bone 
regenerative procedures (4). 
 Thus, immune cells directly contribute to bone remodeling, and the bone healing 
process is known to be negatively affected by estrogen deficiency in elderly women, as 
estrogen promotes osteoclastic activity. Many experimental studies have also shown delayed 
wound healing (impaired bone healing) in ovariectomized rats (5-8). 
 The treatment of bone defects is particularly controversial in the case of osteoporosis. 
The bone grafting procedure is thought to be the most widely used method to enhance bone 
regeneration and repair bone defects, but it has certain drawbacks, including risks during 
collection, hemorrhage, infection, chronic pain, sterilization, storage, especially foreign body 
reactions, and disease transmission (9,10). Therefore, a more effective treatment is needed to 
improve bony defects in osteoporosis. Mesenchymal stem cells (MSCs) have the ability to 
differentiate into osteoblasts and are available from a wide variety of sources. Tissue 
regeneration using autologous stem cells to form a suitable scaffold is an alternative to using 
autografts and allografts (11). The bone-regeneration potential of mesenchymal stem cells has 
been evaluated in bone defects in animals with or without scaffolds (12,13). Currently, 
different methods for efficient tissue regeneration are being developed with various 
combinations of stem cells and scaffolds (14,15).  
 In light of this information, we hypothesized that treatment with BM-MSCs combined 
with bone grafts would facilitate bone repair in osteoporotic bone damage conditions. There is 
little information available about the healing capacity of BM-MSCs used in combination with 
demineralized freeze-dried bone allografts (DFDBAs) for the treatment of calvarial bone 
defects. For this reason, we aimed to evaluate the effects of BM-MSCs and allografts on bone 
healing in ovariectomized rats via the expression of immunohistochemical markers. 
 
MATERIALS AND METHODS 
Animals 
 A total of 48 female Wistar rats (250-300 g) provided by Scientific Application and 
Research Centre of Dicle University (Protocol No: 12-DH-53) were used. All of the 
procedures involved in the experimental protocols were approved by the Animal Ethics 
Committee of Dicle University (Protocol No. 2011/15).The study was performed in 
accordance with the Helsinki Declaration and with the permission of the Governmental 
Animal Protection Committee. Because six animals died, the study was conducted with 42 
rats. Whole animals were provided with commercial rat chow and water ad libitum and were 
maintained on a 12 h light/12 h dark cycle at a temperature of 22 ±1 °C. 
 The animals were anesthetized by the intraperitoneal administration of xylazine and 
ketamine and then subjected to ovariectomy. Ovariectomy was preceded by a 3 cm long 
midline dorsal skin incision, approximately halfway between the middle of the back and the 
base of the tail, according to the method described by Pires-Oliveira et al. (16). The animals 
were monitored for infection. 
 Thirty days following ovariectomy, all animals were anesthetized for the introduction 
of calvarial bone defects. After the head hair was shaved, a longitudinal midsagittal skin 
incision was made to expose the parietal bones, and flaps were retracted in a subperiosteal 
plane, exposing the parietal bones. A 4-mm-diameter full-thickness round-sized cranial defect 
was made unilaterally in the parietal bone using trephine dental drills with saline water 
irrigation. Care was taken to avoid injury to the dura in all animals (17). 
 The animals were randomized. The two groups were separated into three subgroups 
(n=7). Group 1 (control group) was divided into C1; animals with cranial defect only, C2; 
animals with cranial defect with MSCs, and C3; animals with demineralized freeze-dried 
bone allografts with MSCs. Group 2 (ovariectomy group) was divided into O1; animals with 
cranial defect only, O2; animals with cranial defect with MSCs, and O3; animals with 
demineralized freeze-dried bone allografts with MSCs. Eight weeks after the calvarial 
surgery, all of the rats were euthanized with an intraperitoneal overdose of ketamine 
hydrochloride for histological evaluation. 
 
Isolation and culture of rBM-MSCs 
 The isolation and culturing of rBM-MSCs (rat bone marrow mesenchymal stem cells) 
were performed in vitro according to a published protocol (18). MSCs were isolated from the 
bone marrow of rats. Under sterile conditions, femurs and tibias were excised from each rat, 
bone marrow cells were isolated by flushing the bone marrow cavity with complete medium 
(L-DMEM supplemented with 10 % fetal bovine serum [FBS, Gibco/Life Technologies] and 
1% penicillin/streptomycin) delivered through a 21 gauge needle. After washing, the isolated 
bone marrow cells were cultured in complete medium at 37°C in a humidified atmosphere of 
5% CO2 for three days. The unattached cells were removed, and the adhered cells were 
continually cultured until reaching 70-80%confluence. The cells were trypsinized and 
passaged at a ratio of 1:2 or 1:3. The third-passage rBM-MSCs were pooled and used for 
characterization and treatment. 
 
Characterization of rBM-MSCs 
 Undifferentiated rBM-MSCs were subjected to flow cytometry analysis (FACS 
Calibur [BD Biosciences, San Jose, CA]). The cell suspension was spun at 1000 RPM for 5 
minutes and the supernatant was decanted. The pellet was resuspended in 1X PBS. The cells 
were counted with a hemocytometer. The desired total number of cells was added to a flow 
tube (0.5-1 x 10e6 per sample). Wash the cells by adding ~ 1 ml 1X PBS to the flow tube. The 
cell suspension was spun at 1000 RPM for 5 minutes and the supernatant was decanted. 
Gently tap the tube to loosen the cell pellet. An appropriate amount of staining buffer (50 ul 
per 1 x 10e6 cells) was added and Add 1 x 10e6 cells (50 ul) was added to the desired number 
of flow tubes. Finally, immunophenotyping analysis was performed for the antigens CD29, 
CD45, CD54, CD90, CD106, MHC class-I and MHC class-II (BD Biosciences). 
 
In vitro differentiation of rBM-MSCs 
 Adipogenic and osteogenic differentiation was performed in vitro according to a 
published protocol (19). Adipogenic differentiation was performed by incubating rBM-MSCs 
with L-DMEM supplemented with 0.5 mM isobutyl-methylxanthine, 10-6M dexamethasone, 
10 μg/ml insulin and 200 μM indomethacin for two weeks. The medium was refreshed every 
3–4 days. The formation of intracellular lipid droplets, which indicates adipogenic 
differentiation, was confirmed by staining with 0.5% oil red O (Sigma-Aldrich, St. Louis, 
MO).For osteogenic differentiation, the cells were cultured with L-DMEM supplemented with 
100 nM dexamethasone, 0.05 μM ascorbate-2-phosphate, and 10 mM β-glycerophosphate for 
four weeks. After four weeks, osteogenic differentiation was assessed via staining with 2% 
alizarin red S (pH 4.1–4.3; Fluka, Buchs, Switzerland). 
 
Green fluorescent protein (GFP) labeling of rBM-MSCs 
 Mesenchymal stem cells were transfected with pGFP-N (Clontech, Palo Alto, CA) by 
electroporation (Neon Transfection System, Invitrogen, Carlsbad, CA) following the 
instructions provided by the manufacturer. After transfection, the cells were cultured with L-
DMEM (supplemented with 10% FBS), and the transformed cells were selected with G418 
(Gibco/Life Sciences; 200 μg/ml) under standard culture conditions for 48 h. GFP-positive 
cells were maintained in the same medium supplemented with G418 (200 μg/ml) for three 
passages. The numberof GFP+ cells was monitored by flow cytometry;> 90% of the cells 
used in the treatment were GFP positive. 
 
Immunohistochemical analysis of GFP+rBM-MSCs in the tissue 
 Consecutive sections, each 4 µm thick, were taken from each paraffin-embedded 
tissue. To detect GFP+rBM-MSCs, an immunofluorescence staining protocol was performed. 
Slides were deparaffinized with xylene for 5 min twice and rehydrated in a series of graded 
alcohol solutions (70 to 100%). Endogenous peroxidases were inhibited by incubation with 
3% H2O2 in PBS buffer. For antigen retrieval, the samples were heated to 98–99 °C in 
antigen retrieval buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) and incubated for 
30 min in a pressurized vessel. Nonspecific staining was blocked with a mixture of 1.5% 
serum in PBS for 30 min at room temperature, and the sections were incubated with a mouse 
monoclonal anti-GFP antibody (SC-9996) at a 1:50 dilution for 1 h at room temperature. After 
incubation with appropriate fluorophore-conjugated secondary antibodies, the sections were 
covered with mounting medium containing DAPI (Santa Cruz, Heidelberg, Germany). The 
cells were investigated under a fluorescence microscope (Leica DMI 4000B, Wetzlar, 
Germany). 
 
Light microscopy 
 Calvarial tissues were removed and fixed in 10% neutral buffered formaldehyde 
solution for 48 h and then decalcified in 10% ethylene diaminetetraacetic acid (EDTA) 
prepared in 0.1 M Tris-HCl buffer (pH 7.4) for 14 days. The tissues were subsequently 
dehydrated, cleared and embedded in paraffin blocks. Five-micrometer-thick sections were 
cut from these blocks and stained using Gomori’s method to determine ossification. 
 
Immunohistochemical staining 
 Immunohistochemical investigations were performed on tissue preparations embedded 
in paraffin and by using a Zymed Histostain Plus Bulk kit (code: 85-9043, Histostain Plus 
Bulk Kit, Zymed, South San Francisco, CA, USA) and streptavidin-peroxidase (Akbalik and 
Ketani 2013) (19). Briefly, sections were deparaffinized, rehydrated and incubated for 15 min 
in 3% H2O2 in methanol. After the sections were washed in phosphate-buffered saline (PBS), 
antigen retrieval was performed by boiling in 0.01 M citric buffer pH 6.0 for 30 min at 95 ºC 
using a water bath and by cooling for 20 min prior to immunostaining. Sections were then 
washed in PBS and incubated in protein blocking solution (Ultra V Block) for 10 min at room 
temperature to prevent nonspecific binding. Subsequently, the preparations were incubated 
with primary antibodies for 20 h at +4ºC (Table 1) 
 
Table 1. Details of antibodies used. 
 
Antibody Clone, isotype Host Cellular 
localization 
Dilution Supplier  
(Catalog no.) 
Osteopontin/OPN 
(human) 
AKm2A1, monoclonal 
IgG 
Mouse Cytoplasmic 1:200 Santa Cruz (sc-21742) 
Osteonectin/Sparc 
(human) 
H-90, polyclonal IgG Rabbit Cytoplasmic 1:200 Santa Cruz (sc-25574) 
Osteocalcin (human) FL-100, polyclonal IgG Rabbit Cytoplasmic 1:200 Santa Cruz (sc-30044) 
 After being washed in PBS, the sections were incubated with biotinylated secondary 
antibodies for 20 min at room temperature and washed in PBS. Subsequently, the preparations 
were incubated in streptavidin peroxidase conjugate for 20 min at room temperature and were 
then washed with PBS. To visualize the reaction, the sections were treated with 3’3-
diaminobenzidine (DAB) for 5-15 min. After the reaction developed, the sections were 
counterstained with Gill’s hematoxylin, dehydrated through an alcohol series, cleared in 
xylene, and finally mounted in entellan. Negative controls were used for the confirmation of 
the staining. As a negative control, the primary antibodies used for staining were replaced 
with PBS. OPN, OC and ON expression in bone tissue was examined microscopically at x200 
magnification. Immunohistochemical staining results were evaluated semi quantitatively. The 
intensity of positive staining was defined as + weak, ++ medium, +++ strong, + / ++ weak to 
moderate, and ++ / +++ moderate to strong. The slides were examined and photographed 
using a Nikon Eclipse E400 (Nikon, Tokyo, Japan) microscope equipped with a digital 
camera (Nikon Coolpix-4500). 
 
Statistical analysis 
 Kruskal Wallis and Mann-Whitney U tests were used as nonparametric statistical 
analyses. Values of p<0.05 were considered statistically significant. 
 
RESULTS 
Histological findings in calvarial bone tissue 
 In C1 group (animals with cranial defect only, control group), structures (bone 
spicules) characterized by intramembranous ossification were observed along the border of 
the cavity. Furthermore, fibrous tissue was abundant in the cavity and vascularization 
(angiogenesis) had occurred in some areas. In  O1 group (animals with cranial defect only, 
ovariectomy group), intramembranous ossification was observed neither in the cavity nor 
along the border of the cavity, and fibrous tissue was not diffusely distributed, but cellular 
structures were markedly abundant. No significant revascularization was observed between 
control (animals with cranial defect only) and overectomy group rats (animals with cranial 
defect only).  
 O1 (animals with cranial defect only, ovariectomy group), intramembranous 
ossification and osteogenesis had occurred locally, and fibrous tissue was diffuse and 
regularly distributed. Furthermore, vascularization was significantly increased. In group O2 
(animals with cranial defect with MSCs, ovariectomy group), intramembranous ossification 
was observed at a limited level and was localized to the border of the cavity. Furthermore, 
fibrous tissue was irregularly distributed in only some parts of the cavity. The vascularization 
in groups C2 (animals with cranial defect with MSCs, control group)  and O2 (animals with 
cranial defect with MSCs, ovariectomy group) did not differ. 
 When compared to those in the other control groups, the fibrous structures of the 
matrix in group C3 (animals with demineralized freeze-dried bone allografts with MSCs, 
control group) displayed a compact structure as a result of a bone graft having been placed in 
the cavity, and these structures were also tightly adhered to the border of the cavity. 
Intramembranous ossification was observed between the portions of the bone graft. In group 
O3 (animals with demineralized freeze-dried bone allografts with MSCs, ovariectomy group), 
ossification was not observed. The fibrous tissue showed a weak distribution between the 
bone grafts and along the border of the cavity, in a strip-like formation along the latter. 
Furthermore, in contrast to those in the other groups, the stem cells had differentiated into 
adipose cells along the border of the cavity and were present in the form of infiltrating cells 
(Figure 1). 
 
Figure 1. Histological analysis of the defect areas in the rat calvaria bone in the control (C1, C2, and C3) and 
ovariectomy (O1, O2, and O3) groups. The defect was animals with cranial defect only, as shown in Figures C1 
and O1, and the defect areas were treated with stem cells (C2, O2) and stem cells+bone grafts (C3, O3); hb: host 
bone, fc: fibrous connective tissue, bg: bone graft, asterisk: interface between host bone and defect, arrow: 
ossification areas, black arrowhead: bone spicule, blue arrowhead: adipocytes. Gomori’s staining method. 
Scale bars: 100 μm (C1-C2 and O1-O2) and 250 μm (C3-O3). 
 
Immunohistochemistry for osteopontin (OPN) 
 In C1 group (animals with cranial defect only, control group), the osteoprogenitor cells 
along the border of the cavity were not immunoreactive for OPN. However, while the 
osteoblasts and extracellular matrix in the areas of intramembranous ossification along the 
border of the cavity showed weak OPN immunoreactivity, the newly formed blood vessels in 
the cavity were positively stained for OPN (Figure 2-C1). In  O1 group (animals with cranial 
defect only, ovariectomy group), the normal bone tissue showed positive immunoreactivity 
for OPN, but OPN immunoreactivity was limited to the blood vessels in the newly formed 
tissue in the cavity (Figure 2-O1). 
 In group C2 (animals with cranial defect with MSCs, control group), similar to group 
C1, the osteoprogenitor cells along the border of the cavity did not show OPN 
immunoreactivity. Although the osteoblasts in the cavity presented weak OPN staining, OPN 
expression in the blood vessels was increased (Figure 2-C2). In group O2 (animals with 
cranial defect with MSCs, ovariectomy group), staining for OPN was observed neither in the 
osteoprogenitor cells along the border of the cavity nor in the osteoblasts in the cavity, but the 
extracellular matrix and blood vessels were positive for OPN (Figure 2-O2). 
 In group C3 (animals with demineralized freeze-dried bone allografts with MSCs, 
control group), the osteoprogenitor cells along the border of the cavity and the newly formed 
osteoblasts and extracellular matrix in the periphery of the bone graft demonstrated moderate 
OPN immunoreactivity, whereas the blood vessels showed strong OPN immunoreactivity 
(Figure 2-C3). In group O3 (animals with demineralized freeze-dried bone allografts with 
MSCs, ovariectomy group), the newly formed osteoblasts in the periphery of the bone graft 
presented moderate immunoreactivity for OPN, whereas the staining of the blood vessels was 
found to be similar to that observed in group C3 (Figure 2-O3). 
 Figure 2. Osteopontin expression in the rat calvaria bone defect areas in the control (C1, C2, and C3) and 
ovariectomy (O1, O2, and O3) groups. The formation of the groups is shown in figure 1; hb: host bone, fc: 
fibrous connective tissue, bv: blood vessel, bg: bone graft, asterisk: interface between host bone and defect, 
arrow: osteoprogenitor cell, arrowhead: osteoblast. Scale bars: 25 μm (C1), 50 μm (C2-C3-O3), and 100 μm 
(O1-O2). 
 
Immunohistochemistry for osteocalcin (OC) 
 In C1 group (animals with cranial defect only, control group), the osteoprogenitor cells 
along the border of the cavity did not show immunoreactivity for OC, but the osteoblasts 
presented weak OC immunoreactivity. The extracellular matrix in the border of the cavity 
showed moderate staining, and the blood vessels stained positively for OC (Figure 3-C1). In 
O1 group (animals with cranial defect only, ovariectomy group), the osteoprogenitor cells 
also showed OC immunoreactivity, and when compared to that of group C1, the OC 
immunoreactivity of the osteoblasts and extracellular matrix was weaker (Figure 3-O1). 
 Compared with that in the control group, the OC immunoreactivity of the 
osteoprogenitor cells along the border of the cavity in group C2 (animals with cranial defect 
with MSCs, control group)  was found to be negative, but the staining of the extracellular 
matrix and the blood vessels localized to the border of the cavity and the cavity was more 
intense. Furthermore, the osteoblasts in the cavity displayed weak immunoreactivity for OC 
(Figure 3-C2). In group O2 (animals with cranial defect with MSCs, ovariectomy group), the 
osteoprogenitor cells did not show any OC immunoreactivity, and the osteoblasts displayed 
weak OC immunoreactivity. The extracellular matrix of the border of the cavity stained 
strongly for OC and the staining in the cavity was observed to be weak. The OC 
immunoreactivity of the blood vessels was also determined to be strong (Figure 3-O2). 
 In group C3 (animals with demineralized freeze-dried bone allografts with MSCs, 
control group), the newly formed osteoblasts in the periphery of the bone graft displayed OC 
immunoreactivity ranging from moderate to strong, whereas the osteocytes in the ossified 
areas displayed weak OC immunoreactivity. The OC immunoreactivity of the extracellular 
matrix was more homogenous than that in the other groups. Blood vessels also stained 
positively for OC (Figure 3-C3). In group O3 (animals with demineralized freeze-dried bone 
allografts with MSCs, ovariectomy group), the osteoprogenitor cells displayed negative 
staining and the osteoblasts and extracellular matrix were stained moderately. However, the 
blood vessels displayed strong immunoreactivity for OC (Figure 3-O3). 
 
Figure 3. Osteocalcin expression in the rat calvaria bone defect areas in the control (C1, C2, and C3) and 
ovariectomy (O1, O2, and O3) groups. The formation of the groups is shown in Figure 1; hb: host bone, fc: 
fibrous connective tissue, bv: blood vessel, bg: bone graft, asterisk: interface between host bone and defect, 
arrow: osteoprogenitor cell, black arrowhead: osteoblast, blue arrowhead: osteocyte. Scale bars: 50 μm (C1-
C2-O2), and 100 μm (C3-O1-O3). 
 
Immunohistochemistry for osteonectin (ON) 
 In C1 group (animals with cranial defect only, control group), while the 
osteoprogenitor cells along the border of the cavity and the osteoblasts in the cavity stained 
negatively for ON, the extracellular matrix showed weak immunoreactivity, and the blood 
vessels showed moderate immunoreactivity for ON (Figure 4-C1). Group O1(animals with 
cranial defect only, ovariectomy group) showed staining results similar to those of group C1, 
but the extracellular matrix stained weakly (Figure 4-O1). 
 In group C2 (animals with cranial defect with MSCs, control group), the 
osteoprogenitor cells along the border of the cavity were stained negatively, and the 
osteoblasts in the cavity showed weak ON expression. In contrast, the extracellular matrix and 
blood vessels were strongly stained (Figure 4-C2). In group O2 (animals with cranial defect 
with MSCs, ovariectomy group), the osteoprogenitor cells along the border of the cavity did 
not stain, the osteoblasts in the cavity showed weak immunoreactivity for ON. The 
extracellular matrix and blood vessel findings were similar to those of group C2 (Figure 4-
O2). 
 In group C3 (animals with demineralized freeze-dried bone allografts with MSCs, 
control group), the osteoprogenitor cells along the border of the cavity did not express ON, 
but the newly formed osteoblasts in the periphery of the bone graft displayed moderate 
staining. In contrast, the extracellular matrix and blood vessels displayed strong ON 
expression (Figure 4-C3). In group O3 (animals with demineralized freeze-dried bone 
allografts with MSCs, ovariectomy group), the osteoprogenitor cells showed no staining and 
the osteoblasts in the periphery of the bone graft displayed moderate ON expression. It was 
observed that adipose cells had formed in the cavity, yet these cells displayed no 
immunoreactivity. However, the extracellular matrix and blood vessels showed strong ON 
immunoreactivity (Figure 4-O3). 
 Figure 4. Osteonectin expression in the rat calvaria defect areas in the control (C1, C2, and C3) and ovariectomy 
(O1, O2, and O3) groups. The formation of the groups is shown in Figure 1; hb: host bone, fc: fibrous 
connective tissue, bv: blood vessel, bg: bone graft, asterisk: interface between host bone and defect, 
arrowhead: osteoblast. Scale bars: 50 μm (C1-C2-O2) and 100 μm (C3-O1-O3). 
 
Findings of green fluorescent protein (GFP) labeling of RBM-MSCs  
 In the control group, no immune reaction was observed for GFP in animals with 
cranial defect only, without MSCs, whereas GFP and cells (arrows) were observed in C2 
(animals with cranial defect with MSCs, control group)  and C3 (animals with demineralized 
freeze-dried bone allografts with MSCs, control group). Animals with demineralized freeze-
dried bone allografts in the control group, the MSCs transplanted with the graft show the new 
tissue formation (Figure 5). In the overectomy group, no immune reaction was observed for 
GFP in the non- MSCs group (O1), whereas GFP and cells (arrows) were observed in O2 
(animals with cranial defect with MSCs, ovariectomy group) and O3 (animals with 
demineralized freeze-dried bone allografts with MSCs, ovariectomy group). MSCs 
transplanted with the graft in O3 were involved in new tissue formation (Figure 6). 
 Figure 5. GFP fluorescence after immunostaining of the tissue sections from the control group. C1; animals with 
cranial defect only, C2; animals with cranial defect with MSCs, C3; animals with demineralized freeze-dried 
bone allografts with MSCs. Immune reaction (white arrows) was observed in GFP and cells belonging to C2 and 
C3 groups. MSCs transplanted in C3 with the graft showed new bone tissue formation. Scale bars:100 µm. 
 
Figure 6. GFP fluorescence after immunostaining of the tissue sections from the ovariectomy group.O1; animals 
with cranial defect only, O2; animals with cranial defect with MSCs, O3; animals with demineralized freeze-
dried bone allografts with MSCs. Immune reactions (white arrows) were observed in GFP and cells belonging to 
O2 and O3 groups. Graft transplanted MSCs in O3 appeared to participate in new bone tissue formation. Scale 
bars:100 µm 
 In addition, the cell expression of each marker is given in Table 2 for fluorescence intensity. 
 
 
Table 2. Fluorescence intensity. Numbers in panels represent mean fluorescent intensity of 
the cells expressing each marker. 
 
Statistical findings 
Groups p Parameter n Average Rank Different (p<0.05) from factor nr 
(1) C1  
0,0001 
 
1 
7 7,50 (3) 
(2) C2 7 7,50 (3) 
(3) C3 7 18,00 (1)(2) 
(1) C1  
0,0109 
 
2 
7 7,36 (3) 
(2) C2 7 9,71 (3) 
(3) C3 7 15,93 (1)(2) 
(1) C1  
ns 
 
3 
7 11,00  
ns (2) C2 7 11,00 
(3) C3 7 11,00 
(1) C1  
0,0007 
 
4 
7 4,86 (2)(3) 
(2) C2 7 16,57 (1)(3) 
(3) C3 7 11,57 (1)(2) 
(1) O1  
ns 
 
1 
7 11,00  
ns (2) O2 7 11,00 
(3) O3 7 11,00 
(1) O1  
0,001 
 
2 
7 7,50 (3) 
(2) O2 7 7,50 (3) 
(3) O3 7 18,00 (1)(2) 
(1) O1  
ns 
 
3 
7 11,00  
ns (2) O2 7 11,00 
(3) O3 7 11,00 
(1) O1  
0,0004 
 
4 
7 4,00 (2)(3) 
(2) O2 7 15,00 (1) 
(3) O3 7 14,00 (1) 
Table 3. Comparisons of the parameters within the groups (ns; non-significant ; p>0,05)  
1; osteopregenitor cells, 2; osteoblasts, 3;osteocytes, 4;extracelluler matrix 
Parameter Groups p Groups p Groups p 
1 
 
C1 ns C2 
ns 
C3 
0,001 
O1 O2 O3 
2 
 
C1 
0,007 
C2 
0,002 
C3 
ns 
O1 O2 O3 
3 
 
C1 ns C2 
ns 
C3 
ns 
O1 O2 O3 
4 
 
C1 
0,002 
C2 
ns 
C3 
0,015 
O1 O2 O3 
Table 4. Comparisons of the parameters between the control and test groups (ns; non-
significant ; p>0,05) 1; osteopregenitor cells, 2; osteoblasts, 3; osteocytes, 4; extracelluler 
matrix 
 
 When osteopregenitor cells were evaluated between control (animals with 
demineralized freeze-dried bone allografts) and overectomy groups (animals with 
demineralized freeze-dried bone allografts), a significant statistical difference was found 
(Table 3 and 4). When osteoblast cells were evaluated between control and overectomy 
groups, the difference between C1 (animals with cranial defect only, control group)-O1 
(animals with cranial defect only, ovariectomy group) and C2 (animals with cranial defect 
with MSCs, control group) -O2 (animals with cranial defect with MSCs, ovariectomy group) 
groups was found to be statistically significant (Table 3 and 4). And, when the extracellular 
matrix was evaluated, the difference between C1(animals with cranial defect only, control 
group)-O1 (animals with cranial defect only, ovariectomy group) and C3 (animals with 
demineralized freeze-dried bone allografts with MSCs, control group)-O3 (animals with 
demineralized freeze-dried bone allografts with MSCs, ovariectomy group) groups was found 
to be statistically significant (Table 3 and 4).  
 
 
DISCUSSION 
We aimed to investigate the healing capacity of BM-MSCs used with DFDBAs for the 
treatment of Calvarial bone defects, assuming that BM-MSC combined with bone grafts 
would facilitate bone repair under conditions of osteoporotic bone injury. Therefore, the 
effects of BM-MSCs and allografts on bone healing in ovariectomized rats were concluded by 
evaluating immunohistochemical results. 
Sethi et al. (20) evaluated and interpreted both clinically and radiographically by 
studying the changes post 1 week, 1 month, 3 months, and 6 months, respectively. It was 
stated that there was evidence of trabecular formation and calcification. They concluded that 
platelet-rich plasma-enriched DFDBA was a superior inoculant in terms of other available 
inoculants in patients (20). In this experimental study, we observed the successful results of 
demineralized freeze-dried bone allografts.  Called ‘‘Mesenchymal Stem Cell Chondrocytes 
technique’’ was used to reconstruct a 15 mm massive femoral defect (approximately 50% of 
rat femur shaft length) in an experimental study. According to their results, considering the 
high repairability and the excellent biomechanical forces of the repaired femora, they 
concluded that the reconstruction of the large bone defect may be possible (21). 
 In an experimental study in which 8 mm defect was applied to one of the groups in 
which decalcified freeze-dried bone allograft was applied, statistically significant results were 
obtained when compared with the other groups (22). In an experimental study, ovarectomy 
was performed methodologically as in our study. It has been stated that limited proteins are 
known to be involved in the subsequent stages of bone formation and maturation in the 
proteomes of animals (23) 
 As a result of these cellular changes ,osteogenesis becomes impaired and the bone 
formation period is insufficient to repair the increased bone destruction in estrogen 
deficiency-related osteoporosis (24,25). He et al. (8) also found that the femurs of mice with 
OVX-induced osteoporosis showed impaired angiogenesis, osteogenesis, and remodeling in 
their study (8). Calciolari et al. (23) observed immature bone formation both in OVX and 
control calvarial CSDs over a 30-day period (23). Stockmann et al. (26) also observed a 
similar result during the early stage of bone healing on the 30th day. There were no 
differences between the test and control groups, but at 60 days, new bone formation was 
achieved in the MSC group; however, significant pig calvarial bone regeneration was 
measured at day 90 (26). In our study, we observed intramembranous ossification in animals 
with cranial defect only of the healthy control rats , after 60 days. Consistent with other OVX-
induced osteoporosis rat model studies, we did not observe intramembranous ossification 
either in the cavity or along the border of the cavity of animals with cranial defect only with 
ovariectomy group after 8 weeks. However, in cortical bones, such as the calvarial bone, the 
healing process is slower than that in cancellous bone, with a poorer blood supply and less 
bone marrow; thus, much more than 60 days might be necessary for mature bone formation. 
 Recently, it has been stated that the advantages and disadvantages of autogenous, 
allogeneic, xenogenic and alloplastic materials have gained meaning in periodontal treatment. 
(27). Kurkalli et al. (28) concluded that the placement of the osteogenic composite in a large 
deficient area of the parietal bone of the skull of rats resulted in a large demineralized bone 
matrix particle structure, fully reconstituted hematopoietic microenvironment within thirty 
days, and a well-integrated normal smooth bone. (28). Intini et al. (29) found that 
demineralized freeze-dried bone was not effective enough to induce bone formation in rat 
calvaria 8 weeks after surgery (29). Caplanis et al. (30) did not find any histological effects on 
bone formationin canine defects treated with demineralized freeze-dried bone allografts after 
4 weeks (30). Bertolai et al. (31) have successfully used freeze-dried bone as a graft material 
in the treatment of maxillary atrophy, as in our study. (31). 
 In the meta-analysis, the authors concluded that MSCs improved bone regeneration, 
and it is preferable to use MSCs with an appropriate scaffold. Koob S et al. mentioned that 
mesenchymal stem cells (MSCs) enhance bone formation in calvarial defects (32). Moreover, 
in large animal studies, autologous MSCs transplanted alone or in combination with different 
bone substitutes were found to significantly increase bone formation in critical-sized defects 
(9). Kandal et al. suggested that the combined use of demineralized bone matrix with MSCs 
increases the osteoinductive responses in the frontal bone of rats. They suggested that this 
combination can provide enhanced craniofacial bone reconstruction results at the end of 12 
weeks (33). In another experimental study, the utilization of mesenchymal stem cells with 
platelet-rich plasma and synthetic bone substitutes was found to enhance new bone formation 
(34). Semyari et al. observed the overall recovery of a bony defect treated with mesenchymal 
stem cells on different scaffolds with membranes after 8 weeks of calvarial surgery in rabbits 
(35). 
 Osteopontin has been implicated as being an important factor in bone 
remodeling. Research suggests it plays a role in attaching osteoclasts to the mineral matrix of 
bones and in the regulation of normal mineralization within the extracellular matrices of 
bones and teeth. Osteocalcin and osteonectin are not observed during initial crystal formation 
but are seen in the later stages of bone formation (36). Therefore, we chose these three bone 
markers to assess the bone formation activity. We also observed the effect of estrogen 
deficiency on bone healing via the expression of these bone markers, as there are few studies 
on this issue. In our study, the osteoblasts and extracellular matrix staining for these proteins 
was weak in animals with cranial defect only in the control and ovariectomy groups without 
MSCs. Histological and immunohistochemical evaluation revealed that the findings obtained 
for the extracellular matrix, ossification and blood vessels were similar between groups O2 
(animals with cranial defect with MSCs, ovariectomy group) and C2 (animals with cranial 
defect with MSCs, control group). Thus, estrogen deficiency may not influence the expression 
of bone markers, which is consistent with the findings of Tera Tde et al. (36). According to 
the results of this study, more new bone formation was observed in defects treated with MSCs 
alone than was observed in animals with cranial defect only. However, the combination of 
DFDBA/MSCs in animals with demineralized freeze-dried bone allografts of ovariectomy 
group was not as effective on compact intramembranous ossification at the end of the 8 weeks 
as expected. 
 Akita et al. found that there were no significant differences in 4 mm cranial rat defects 
among groups treated with MSCs only or MSCs with FGF-BMP at 8 weeks after 
transplantation (17). Similar to our study, Wang et al. created bony defects in ovariectomized 
rabbits and treated the defects with mesenchymal stem cells/decalcified bone matrix. Three 
months later, the authors concluded that the defect treatment was ineffective for the 
osteoporotic state and that the bone formation was significantly worse than that of the control 
group (37). 
 The properties of scaffolds are important for the migration, proliferation and 
differentiation of living cells during bone regeneration. In this study, the combination of 
human (DFDBAs) and animal (rBM-MSCs) scaffolds may be biologically incompatible. 
However, the osteogenic potential of the DFDBA may be diminished during the production 
process. Additionally, bone healing may have been negatively affected by the absence of a 
collagen membrane in the scaffold. 
 There are some limitations to the current study. It would be better to evaluate bone 
formation with histomorphometric parameters than histochemical staining. In addition, a 
collagen membrane may be used with the scaffold for 12 weeks to achieve complete bone 
regeneration. In conclusion, stem cell therapy could be an option to manage impaired bone 
formation. However, to achieve compact bone formation it is preferential to use proper 
scaffolds loaded with BM-MSCs for the appropriate healing time. Because there are limited 
studies in this field, further studies are required to investigate the proliferation and 
differentiation of MSCs in different scaffolds for the enhancement of impaired bone 
formation.  
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